Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 28, 2007

Daicel and Novasep Collaborate on Large-Scale Chiral Separation Technology

  • Daicel Chemical Industries and Groupe Novasep are partnering to streamline the use of chiral chromatography to manufacture late-stage clinical and commercial chiral intermediates and APIs.

    Daicel plans to identify the best chiral stationary phase (CSP) from their library of commercial and developmental CSPs. Novasep Process will provide process optimization services, using its computer simulation software and full process development.

    The intended result of this combined approach is to deliver guaranteed scale-up, optimum performance, and best economics for large-scale separations, explains Jean Blehaut, president of Novasep Process’ parma business unit.

    “Today, several chiral drugs are commercially produced with chromatographic technologies. Such drugs include Pfizer’s Zoloft, UCB Pharma’s Keppra, Lundbeck’s/Forest Laboratories’ Cipralex/Lexapro, and Cephalon’s Nuvigil,” he points out.

    “But the pharmaceutical industry is just discovering the potential of chiral chromatography to bring NCEs to the market faster. The existing commercial projects have demonstrated that it is often cheaper to produce single enantiomeric drugs with chromatography than use traditional technologies such as crystallization and/or asymmetric synthesis.”

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »